In a large phase III trial conducted in patients with HER2 altered metastatic disease, whose cancer had progressed despite trastuzumab-containing therapy, the combination of the chemotherapy drug capecitabine plus lapatinib was superior to capecitabine alone [14]. The gene discussed is ERBB2; the disease is cancer.